Fig. 1. Mismatch repair protein expression in synchronous endometrial and ovarian endometrioid adenocarcinoma. Patient #5 shows the concurrent loss of MLH1 and PMS2 expression in both endometrial and ovarian tumors, indicating an MLH1 aberration. Patient #28 exhibits retained MSH2 expression and loss of MSH6 in both endometrial and ovarian tumors, suggesting an MSH6 aberration.
